Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review.
Identifieur interne : 000449 ( Main/Exploration ); précédent : 000448; suivant : 000450Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review.
Auteurs : Michael D. Staudt [Canada] ; Andrea R. Di Sebastiano ; Hu Xu ; Mandar Jog ; Susanne Schmid ; Paula Foster ; Matthew O. HebbSource :
- Gerontology [ 1423-0003 ] ; 2016.
English descriptors
- KwdEn :
- Brain (metabolism), Cell- and Tissue-Based Therapy (methods), Dopamine (metabolism), Fetal Tissue Transplantation (methods), Genetic Vectors, Glial Cell Line-Derived Neurotrophic Factor (therapeutic use), Humans, Induced Pluripotent Stem Cells (transplantation), Mesencephalon (transplantation), Nerve Growth Factors (therapeutic use), Neurturin (therapeutic use), Parkinson Disease (metabolism), Parkinson Disease (therapy).
- MESH :
- chemical , metabolism : Dopamine.
- metabolism : Brain, Parkinson Disease.
- methods : Cell- and Tissue-Based Therapy, Fetal Tissue Transplantation.
- chemical , therapeutic use : Glial Cell Line-Derived Neurotrophic Factor, Nerve Growth Factors, Neurturin.
- therapy : Parkinson Disease.
- transplantation : Induced Pluripotent Stem Cells, Mesencephalon.
- Genetic Vectors, Humans.
Abstract
Parkinson's disease (PD) affects an estimated 7-10 million people worldwide and remains without definitive or disease-modifying treatment. There have been many recent developments in cell-based therapy (CBT) to replace lost circuitry and provide chronic biological sources of therapeutic agents to the PD-affected brain. Early neural transplantation studies underscored the challenges of immune compatibility, graft integration and the need for renewable, autologous graft sources. Neurotrophic factors (NTFs) offer a potential class of cytoprotective pharmacotherapeutics that may complement dopamine (DA) replacement and CBT strategies in PD. Chronic NTF delivery may be an integral goal of CBT, with grafts consisting of autologous drug-producing (e.g., DA, NTF) cells that are capable of integration and function in the host brain. In this mini-review, we outline the past experience and recent advances in NTF technology and CBT as promising and integrated approaches for the treatment of PD.
DOI: 10.1159/000438701
PubMed: 26330171
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000325
- to stream PubMed, to step Curation: 000325
- to stream PubMed, to step Checkpoint: 000325
- to stream Ncbi, to step Merge: 001C97
- to stream Ncbi, to step Curation: 001C97
- to stream Ncbi, to step Checkpoint: 001C97
- to stream Main, to step Merge: 000450
- to stream Main, to step Curation: 000449
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review.</title><author><name sortKey="Staudt, Michael D" sort="Staudt, Michael D" uniqKey="Staudt M" first="Michael D" last="Staudt">Michael D. Staudt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ont., Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ont.</wicri:regionArea><wicri:noRegion>Ont.</wicri:noRegion></affiliation></author><author><name sortKey="Di Sebastiano, Andrea R" sort="Di Sebastiano, Andrea R" uniqKey="Di Sebastiano A" first="Andrea R" last="Di Sebastiano">Andrea R. Di Sebastiano</name></author><author><name sortKey="Xu, Hu" sort="Xu, Hu" uniqKey="Xu H" first="Hu" last="Xu">Hu Xu</name></author><author><name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name></author><author><name sortKey="Schmid, Susanne" sort="Schmid, Susanne" uniqKey="Schmid S" first="Susanne" last="Schmid">Susanne Schmid</name></author><author><name sortKey="Foster, Paula" sort="Foster, Paula" uniqKey="Foster P" first="Paula" last="Foster">Paula Foster</name></author><author><name sortKey="Hebb, Matthew O" sort="Hebb, Matthew O" uniqKey="Hebb M" first="Matthew O" last="Hebb">Matthew O. Hebb</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26330171</idno><idno type="pmid">26330171</idno><idno type="doi">10.1159/000438701</idno><idno type="wicri:Area/PubMed/Corpus">000325</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000325</idno><idno type="wicri:Area/PubMed/Curation">000325</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000325</idno><idno type="wicri:Area/PubMed/Checkpoint">000325</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000325</idno><idno type="wicri:Area/Ncbi/Merge">001C97</idno><idno type="wicri:Area/Ncbi/Curation">001C97</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C97</idno><idno type="wicri:Area/Main/Merge">000450</idno><idno type="wicri:Area/Main/Curation">000449</idno><idno type="wicri:Area/Main/Exploration">000449</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review.</title><author><name sortKey="Staudt, Michael D" sort="Staudt, Michael D" uniqKey="Staudt M" first="Michael D" last="Staudt">Michael D. Staudt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ont., Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ont.</wicri:regionArea><wicri:noRegion>Ont.</wicri:noRegion></affiliation></author><author><name sortKey="Di Sebastiano, Andrea R" sort="Di Sebastiano, Andrea R" uniqKey="Di Sebastiano A" first="Andrea R" last="Di Sebastiano">Andrea R. Di Sebastiano</name></author><author><name sortKey="Xu, Hu" sort="Xu, Hu" uniqKey="Xu H" first="Hu" last="Xu">Hu Xu</name></author><author><name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name></author><author><name sortKey="Schmid, Susanne" sort="Schmid, Susanne" uniqKey="Schmid S" first="Susanne" last="Schmid">Susanne Schmid</name></author><author><name sortKey="Foster, Paula" sort="Foster, Paula" uniqKey="Foster P" first="Paula" last="Foster">Paula Foster</name></author><author><name sortKey="Hebb, Matthew O" sort="Hebb, Matthew O" uniqKey="Hebb M" first="Matthew O" last="Hebb">Matthew O. Hebb</name></author></analytic><series><title level="j">Gerontology</title><idno type="eISSN">1423-0003</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brain (metabolism)</term><term>Cell- and Tissue-Based Therapy (methods)</term><term>Dopamine (metabolism)</term><term>Fetal Tissue Transplantation (methods)</term><term>Genetic Vectors</term><term>Glial Cell Line-Derived Neurotrophic Factor (therapeutic use)</term><term>Humans</term><term>Induced Pluripotent Stem Cells (transplantation)</term><term>Mesencephalon (transplantation)</term><term>Nerve Growth Factors (therapeutic use)</term><term>Neurturin (therapeutic use)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cell- and Tissue-Based Therapy</term><term>Fetal Tissue Transplantation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Nerve Growth Factors</term><term>Neurturin</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Induced Pluripotent Stem Cells</term><term>Mesencephalon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Genetic Vectors</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) affects an estimated 7-10 million people worldwide and remains without definitive or disease-modifying treatment. There have been many recent developments in cell-based therapy (CBT) to replace lost circuitry and provide chronic biological sources of therapeutic agents to the PD-affected brain. Early neural transplantation studies underscored the challenges of immune compatibility, graft integration and the need for renewable, autologous graft sources. Neurotrophic factors (NTFs) offer a potential class of cytoprotective pharmacotherapeutics that may complement dopamine (DA) replacement and CBT strategies in PD. Chronic NTF delivery may be an integral goal of CBT, with grafts consisting of autologous drug-producing (e.g., DA, NTF) cells that are capable of integration and function in the host brain. In this mini-review, we outline the past experience and recent advances in NTF technology and CBT as promising and integrated approaches for the treatment of PD.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Di Sebastiano, Andrea R" sort="Di Sebastiano, Andrea R" uniqKey="Di Sebastiano A" first="Andrea R" last="Di Sebastiano">Andrea R. Di Sebastiano</name><name sortKey="Foster, Paula" sort="Foster, Paula" uniqKey="Foster P" first="Paula" last="Foster">Paula Foster</name><name sortKey="Hebb, Matthew O" sort="Hebb, Matthew O" uniqKey="Hebb M" first="Matthew O" last="Hebb">Matthew O. Hebb</name><name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name><name sortKey="Schmid, Susanne" sort="Schmid, Susanne" uniqKey="Schmid S" first="Susanne" last="Schmid">Susanne Schmid</name><name sortKey="Xu, Hu" sort="Xu, Hu" uniqKey="Xu H" first="Hu" last="Xu">Hu Xu</name></noCountry><country name="Canada"><noRegion><name sortKey="Staudt, Michael D" sort="Staudt, Michael D" uniqKey="Staudt M" first="Michael D" last="Staudt">Michael D. Staudt</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000449 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000449 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26330171
|texte= Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26330171" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |